<?xml version="1.0" encoding="UTF-8"?>
<p>Soon after the DVPS was identified, clinical and epidemiological data strongly associated it with second heterotypic DENV infections and also with primary DENV infections of infants born to dengue-immune mothers 
 <sup>
  <xref rid="ref-11" ref-type="bibr">11</xref>, 
  <xref rid="ref-73" ref-type="bibr">73</xref>
 </sup>. Pathology studies have consistently demonstrated human DENV infection target cells to be of myeloid lineage 
 <sup>
  <xref rid="ref-74" ref-type="bibr">74</xref>
 </sup>. When DENV infections occur 
 <italic>in vitro</italic> or 
 <italic>in vivo</italic> in the presence of sub-neutralizing dengue antibodies, enhanced infections/disease may result 
 <sup>
  <xref rid="ref-35" ref-type="bibr">35</xref>, 
  <xref rid="ref-75" ref-type="bibr">75</xref>
 </sup>. Indeed, the peak of early illness viremias or antigenemia successfully predicted disease severity 
 <sup>
  <xref rid="ref-26" ref-type="bibr">26</xref>, 
  <xref rid="ref-76" ref-type="bibr">76</xref>, 
  <xref rid="ref-77" ref-type="bibr">77</xref>
 </sup>. This phenomenon, antibody-dependent enhancement (ADE) of DENV infection of Fc receptorâ€“bearing cells, differs from infection of these same cells in the absence of antibodies by two mechanisms: an increase in the number of cells infected (extrinsic ADE) or an increase in the intracellular production of DENV (intrinsic ADE) 
 <sup>
  <xref rid="ref-78" ref-type="bibr">78</xref>
 </sup>.
</p>
